

**AAMP Scottsdale**

**Advanced Applications in Chronic Digestive Illness**

**August 21<sup>st</sup> through 23<sup>rd</sup> 2020**

**18 AMA PRA Category-1 CME (10 Pharmacology and 2 Ethics CE)**

---

**FRIDAY**

**Morning Theme: Integrative Approaches to Inflammatory Bowel Disorders**

8:00 – 8:15     Jeremy Phillips    Welcome and Opening Information

8:15 – 9:15     Anderson            Lab assessments to consider for a truly integrative GI work-up

What can the clinician look at beyond “basic labs” and endoscopy in the GI patient? When is it appropriate to add more studies and what can they show us? In this session Dr. Anderson will give common areas to look including endocrine, immunological, toxic and many other areas.

9:15 – 9:45     Grutz                Keeping the IBD patient alive and engaged: The Mind-Body Connection

Regardless of the direction an IBD patient wishes to go with their healthcare the disease process affects every aspect of their life. In this session a deep dive into the factors that affect patient motivation and overall health and healing will be discussed.

9:45 – 10:15    Grutz                Clinical Insights in IBD work-up: Things not to miss

As a specific follow-on to Dr. Anderson’s prior presentation this session will direct the clinician to specific points in the medical work-up of the patient with IBD not to miss. This discussion is based on patient case outcomes and current standard of care.

10:15 – 11:00                            BREAK

11:00 – 12:00    Anderson            Biological Medications in GI Cases: Pharmacology and Safety

Targeted biological therapies have in one way revolutionized some chronic GI diseases. In other ways they have complicated the landscape, monitoring and management of the GI patient. The positive and negative aspects of these therapies will be discussed. Common drugs, adverse events and appropriate monitoring will be discussed.

12:00 – 12:45    Anderson            Managing Biological Medications: Integration of Natural Agents

As a follow up to the prior presentation Dr. Anderson will discuss the methods used to assess safety and compatibility of natural agents and biological drugs. What specific agents are helpful and can they improve and make more safe the biological drug therapies?

12:45 – 1:15     Michael Gazsi, ND     Non-CME Scientific Presentation – Professional Nutritionals

Using Powdered Formulations in GI Cases to Improve Outcomes and Compliance

1:15 – 2:30                                LUNCH

### **Afternoon Theme: Dysbiosis - Introduction to SIBO-SIFO Identifying and Assessing the Patient**

2:30 – 3:00 Siebecker SIBO Presentation, Pathophysiology and Spotting the SIBO Patient

Dr. Siebecker will kick off the SIBO Theme with discussion on subtypes of SIBO and their new classifications, symptoms and how those symptoms are created, clinical indicators that help us spot potential SIBO patients, and how chronic SIBO is or isn't.

3:00 – 3:30 Khangura SIBO Testing and Interpretation Part – 1

SIBO testing and interpretation is unique and can be confusing to learn. Dr. Khangura will use his clinical and laboratory experience to clarify the methods of SIBO testing and their clinical uses. Examples of test results will be discussed and explained.

3:30 – 4:00 Guy Citrin, N.D. Non-CME Scientific Presentation – Microbiome Labs

The spectacular role of the human microbiome in preventing post-prandial or metabolic endotoxemia, the number one cause of mortality worldwide

4:00 – 4:45 BREAK

4:45 – 5:15 Khangura SIBO Testing and Interpretation Part – 2

SIBO testing and interpretation is unique and can be confusing to learn. Dr. Khangura will use his clinical and laboratory experience to clarify the methods of SIBO testing and their clinical uses. Examples of test results will be discussed and explained.

5:15 – 5:45 All Clinical Panel Discussion – CME

IBD and SIBO; Diagnostic Considerations and Clinical Approach

Focused moderated clinical panel discussion and clinical questions from delegates.

### **SATURDAY**

#### **Morning Theme: Dysbiosis - Introduction to SIBO-SIFO Therapeutics and Case Studies**

8:00 – 9:00 Siebecker SIBO Treatment Part 1: Hydrogen and Methane

The various treatment options proven effective for hydrogen and methane cases of SIBO will be explained by Dr. Siebecker, including pharmaceutical antibiotics, herbal antibiotics, elemental diet and diet, as well as how to follow a methodical treatment approach to increase clinical success.

9:00 – 10:00 Khangura Latest Therapeutics Part – 2: Hydrogen Sulfide (H<sub>2</sub>S) SIBO

In some cases where testing is negative for SIBO but symptoms are present hydrogen sulfide SIBO can be a cause which does not show up on standard SIBO breath tests. In this presentation Dr. Khangura will break down the signs and symptoms of H<sub>2</sub>S SIBO and discuss appropriate treatment strategies.

10:00 – 10:45 BREAK

10:45 – 12:00 Khangura SIFO Overview and Case Studies in SIBO-SIFO

Fungal overgrowth is common in GI disorders. In the setting of small intestinal dysfunction SIFO is a critical cause to treat or rule out. In this presentation the common presentation of SIFO and therapies will be outlined using case studies.

12:00 – 12:30 Bob Miller, CTN Non-CME Scientific Presentation - NutriGenetic Research Institute  
Genetic Polymorphisms Resulting in Mast Cell Activation in Chronic Digestive Disorders

12:30 – 1:45 LUNCH

**Afternoon Theme: Dysbiosis - Introduction to SIBO-SIFO Extra-intestinal Manifestations and Prevention**

1:45 – 2:45 Siebecker Relapse Prevention: Keeping the Patient Healthy!

After SIBO eradication, the work is not done. Since there is a high prevalence of relapse, preventative measures must be considered. Dr. Siebecker will discuss natural and pharmaceutical prokinetics as well as other strategies and share her top recommendations for overall treatment success.

2:45 – 3:45 Weinstock Extra-intestinal Manifestations of SIBO

There are many syndromes that people suffer from on a daily basis for which doctors have no answers and have no interest in exploring contributing factors. By looking inwards towards the gut we can find new answers for RLS, rosacea, and chronic pelvic pain syndrome.

3:45 – 4:15 Marvin Singh, M.D. Non-CME Scientific Presentation - Sovereign Laboratories  
Genetic and Decoding Inflammation of The Gut Microbiome & Extending Longevity

4:15 – 5:00 BREAK

5:00 – 6:00 All Extended Clinical Panel Discussion – CME  
SIBO: “A-Z” Discussion with the Experts

Focused moderated clinical panel discussion and clinical questions from delegates.

**SUNDAY**

**Morning Theme: GI Effects of Mast Cell, Allergy, Sensitivities and Infectious Agents**

8:30 – 9:00 Anderson Food Allergy & Sensitivity: Meaning and Implications for Treatment

Why (and with what implications) would a clinician wish to look to food allergy, sensitivity or intolerance in GI cases, and how does one make sense of the differing laboratory methods. In this session Dr. Anderson will discuss the immunology of food reactions and the categories of testing which can assess those reactions.

9:00 – 10:00 Weinstock MCAS (Mast Cell Activation) as Cause of SIBO (and other conditions)

Most people are unfamiliar with MCAS. It is unknown to most people that MCAS can be associated and cause SIBO, restless legs syndrome, and tinnitus. At the end of the lecture the attendee should be able to determine how MCAS occurs, how it is diagnosed and treated, and how it can cause SIBO.

10:00 – 10:30 Anderson Infectious Agents to Manage in GI Cases – 1

What are the common and uncommon GI infections to consider in the GI patient? How do biofilms fit in to the testing and assessment? When are serum versus stool tests indicated?

10:30 – 11:15 BREAK

11:15 – 11:45 Anderson Infectious Agents to Manage in GI Cases – 2

In this portion of the infectious disease presentation Dr. Anderson will turn to therapeutics including natural and prescription medication uses.

11:45 – 12:15 Grutz The Role of Lymphatic Activity and Health in Chronic Cases

Lymphatic activity is critical to all health. In the patient with any chronic illness it is easy to overlook this critical system. In this presentation a way of assessing and treating lymphatic activity will be presented.

12:15 – 12:45 Anderson Biofilms and GI Health: Latest Updates

As follow up to the infectious disease presentation earlier Dr. Anderson will delve into the intricacies of biofilm agents, when the different levels of agent are appropriate and how to know to taper them.

12:45 – 1:15 Grutz Fecal Microbiota Transplants (FMT): Updates and Role in Treatment

FMT is a growing therapy in chronic GI illness. It may be limited in some countries to particular diseases and more open in other countries to broader use. In this presentation an overview of FMT and discussion of its clinical use will be made.

1:15 – 2:15 LUNCH

### **Afternoon Theme: GI Cancers – Clinical Pearls**

2:15 – 4:15 Anderson GI Cancers: Clinical Pearls, Management and Prevention

While we have had entire conferences about oncology it is necessary and appropriate to include GI specific cancer therapies. In this focused session Dr. Anderson will relate his experience and his review of the current data regarding the approach to GI cancers. GI specific therapies and implementation will be discussed.

4:15 – 4:30 COMFORT BREAK

4:30 – 5:00 Clinical Panel – CME

Focused moderated clinical panel discussion and clinical questions from delegates.

Immunology and GI Illness – Intersections Between Cancer, Immune Response and GI Illness

5:00

ADJOURN